Medicine and Dentistry
Patient
100%
Randomized Controlled Trial
91%
Myocardial Infarction
65%
Surgery
64%
Cardiac Troponin
62%
Inpatient
49%
Troponin
40%
Amaurosis
38%
Analysis
37%
Recurrent Disease
36%
Mercaptopurine
36%
Crohn's Disease
36%
Acute Coronary Syndrome
34%
Heart Muscle Injury
29%
Evaluation Study
28%
Group Trial
24%
Neck
24%
Enalapril Maleate
23%
Diagnosis
22%
Hospital
21%
Rehabilitation Engineering
16%
Assay
16%
Woman
15%
Arm
15%
Hazard Ratio
14%
Cost-Effectiveness Analysis
14%
Apoplexy
13%
Prophylaxis
13%
Age
13%
Therapeutic Procedure
12%
Granulocyte Colony Stimulating Factor
12%
Transfusion
12%
DNA Template
12%
Cohort Analysis
12%
Thorax Pain
12%
Femur
12%
Adult
12%
Breast Cancer
12%
Adjuvant Chemotherapy
12%
Radiation Therapy
12%
Placebo
12%
Coronary Computed Tomography Angiography
12%
Gemcitabine
12%
Paget's Disease
12%
Non Small Cell Lung Cancer
12%
Orthotics
12%
Osteoarthritis
12%
Follow up
11%
Smoking
11%
Death
10%
Nursing and Health Professions
Patient
56%
Troponin
40%
Heart Infarction
32%
Evaluation Study
26%
Standard
25%
Surgery
18%
Acute Coronary Syndrome
17%
Dose
15%
Inpatient
15%
Diagnosis
15%
Heart Muscle Injury
15%
Clinical Effectiveness
13%
Prophylaxis
12%
Adjuvant Chemotherapy
12%
Transfusion
12%
Non Small Cell Lung Cancer
12%
Hybrid
12%
Radiotherapy
12%
Ward
12%
Gemcitabine
12%
Dementia
12%
Breast Cancer
12%
Cognitive Defect
12%
Granulocyte Colony Stimulating Factor
12%
Cost Effectiveness Analysis
12%
Flow
12%
Delirium
12%
Dyspnea
12%
Morphine
12%
Placebo
12%
Hemoglobin
10%
Assay
10%
Pneumonia
9%
Hospital
8%
Event Free Survival
8%
Discharge
7%
Hospitalization
6%
Death
5%
Low Drug Dose
5%
Troponin I
5%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
36%
Blindness
26%
Recurrent Disease
24%
Mercaptopurine
24%
Crohn Disease
24%
Randomized Controlled Trial
24%
Heart Infarction
22%
Troponin
17%
Modified Release
12%
Morphine
12%
Breast Cancer
12%
Cognitive Defect
12%
Dyspnea
12%
Dementia
12%
Granulocyte Colony Stimulating Factor
12%
Delirium
12%
Enalapril Maleate
12%
Chemotherapy
12%